Bridge Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$321K
- Investors
-
3
Bridge Therapeutics General Information
Description
Operator of a pharmaceutical company intended for the treatment of chronic pain in opioid-experienced patients. The company offers a better delivery of buprenorphine-naloxone for opioid use disorder (OUD) and drug combination, enabling medical researchers to improve the lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and non-addictive.
Contact Information
Website
www.bridgetherapeutics.comCorporate Office
- 217 Country Club Park
- Suite 325
- Birmingham, AL 35213
- United States
Corporate Office
- 217 Country Club Park
- Suite 325
- Birmingham, AL 35213
- United States
Bridge Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 18-Dec-2023 | $321K | Completed | Clinical Trials - Phase 4 | ||
| 3. Early Stage VC | 01-Jun-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 01-Dec-2019 | $3.3M | $5.3M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series AA) | 24-Apr-2019 | $2M | $2M | Completed | Clinical Trials - General |
Bridge Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series AB | ||||||||
| Series AA |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Bridge Therapeutics Comparisons
Industry
Financing
Details
Bridge Therapeutics Competitors (12)
One of Bridge Therapeutics’s 12 competitors is Sollis Therapeutics, a Venture Capital-Backed company based in Hilliard, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sollis Therapeutics | Venture Capital-Backed | Hilliard, OH | ||||
| Semnur Pharmaceuticals | Formerly VC-backed | Palo Alto, CA | ||||
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Brixton Biosciences | Venture Capital-Backed | Cambridge, MA |
Bridge Therapeutics Patents
Bridge Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10195206-B2 | Two-component pharmaceutical composition for the treatment of pain | Inactive | 14-Jun-2005 | ||
| US-20060281775-A1 | Two-component pharmaceutical composition for the treatment of pain | Inactive | 14-Jun-2005 | ||
| US-20100093712-A1 | Two-component pharmaceutical composition for the treatment of pain | Active | 14-Jun-2005 | ||
| US-20140080818-A1 | Two-component pharmaceutical composition for the treatment of pain | Active | 14-Jun-2005 | ||
| US-20190388431-A2 | Two-component pharmaceutical composition for the treatment of pain | Inactive | 14-Jun-2005 | A61K31/5415 |
Bridge Therapeutics Signals
Bridge Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| EJME | Real Estate | Minority | ||
| Keiretsu Forum | Angel Group | Minority |
Bridge Therapeutics FAQs
-
When was Bridge Therapeutics founded?
Bridge Therapeutics was founded in 2016.
-
Where is Bridge Therapeutics headquartered?
Bridge Therapeutics is headquartered in Birmingham, AL.
-
What is the size of Bridge Therapeutics?
Bridge Therapeutics has 7 total employees.
-
What industry is Bridge Therapeutics in?
Bridge Therapeutics’s primary industry is Drug Discovery.
-
Is Bridge Therapeutics a private or public company?
Bridge Therapeutics is a Private company.
-
What is Bridge Therapeutics’s current revenue?
The current revenue for Bridge Therapeutics is .
-
How much funding has Bridge Therapeutics raised over time?
Bridge Therapeutics has raised $11.6M.
-
Who are Bridge Therapeutics’s investors?
, EJME, and Keiretsu Forum have invested in Bridge Therapeutics.
-
Who are Bridge Therapeutics’s competitors?
Sollis Therapeutics, Semnur Pharmaceuticals, Centrexion Therapeutics, Xalud Therapeutics, and Brixton Biosciences are some of the 12 competitors of Bridge Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process